Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Department of Biology, Johns Hopkins University, Baltimore, Maryland.
Cancer Prev Res (Phila). 2023 Oct 2;16(10):561-570. doi: 10.1158/1940-6207.CAPR-23-0112.
FGFR3 and PIK3CA are among the most frequently mutated genes in bladder tumors. We hypothesized that recurrent mutations in these genes might be caused by common carcinogenic exposures such as smoking and other factors. We analyzed 2,816 bladder tumors with available data on FGFR3 and/or PIK3CA mutations, focusing on the most recurrent mutations detected in ≥10% of tumors. Compared to tumors with other FGFR3/PIK3CA mutations, FGFR3-Y375C was more common in tumors from smokers than never-smokers (P = 0.009), while several APOBEC-type driver mutations were enriched in never-smokers: FGFR3-S249C (P = 0.013) and PIK3CA-E542K/PIK3CA-E545K (P = 0.009). To explore possible causes of these APOBEC-type mutations, we analyzed RNA sequencing (RNA-seq) data from 798 bladder tumors and detected several viruses, with BK polyomavirus (BKPyV) being the most common. We then performed IHC staining for polyomavirus (PyV) Large T-antigen (LTAg) in an independent set of 211 bladder tumors. Overall, by RNA-seq or IHC-LTAg, we detected PyV in 26 out of 1,010 bladder tumors with significantly higher detection (P = 4.4 × 10-5), 25 of 554 (4.5%) in non-muscle-invasive bladder cancers (NMIBC) versus 1 of 456 (0.2%) of muscle-invasive bladder cancers (MIBC). In the NMIBC subset, the FGFR3/PIK3CA APOBEC-type driver mutations were detected in 94.7% (18/19) of PyV-positive versus 68.3% (259/379) of PyV-negative tumors (P = 0.011). BKPyV tumor positivity in the NMIBC subset with FGFR3- or PIK3CA-mutated tumors was also associated with a higher risk of progression to MIBC (P = 0.019). In conclusion, our results support smoking and BKPyV infection as risk factors contributing to bladder tumorigenesis in the general patient population through distinct molecular mechanisms.
Tobacco smoking likely causes one of the most common mutations in bladder tumors (FGFR3-Y375C), while viral infections might contribute to three others (FGFR3-S249C, PIK3CA-E542K, and PIK3CA-E545K). Understanding the causes of these mutations may lead to new prevention and treatment strategies, such as viral screening and vaccination.
FGFR3 和 PIK3CA 是膀胱癌中最常发生突变的基因之一。我们假设这些基因中的复发性突变可能是由常见的致癌暴露引起的,如吸烟和其他因素。我们分析了 2816 例有 FGFR3 和/或 PIK3CA 突变数据的膀胱癌,重点分析了在≥10%的肿瘤中检测到的最常见的突变。与 FGFR3/PIK3CA 其他突变的肿瘤相比,FGFR3-Y375C 在吸烟者中的肿瘤中比从不吸烟者更常见(P=0.009),而几种 APOBEC 型驱动突变在从不吸烟者中富集:FGFR3-S249C(P=0.013)和 PIK3CA-E542K/PIK3CA-E545K(P=0.009)。为了探索这些 APOBEC 型突变的可能原因,我们分析了 798 例膀胱癌的 RNA 测序(RNA-seq)数据,并检测到几种病毒,其中 BK 多瘤病毒(BKPyV)最为常见。然后,我们在 211 例独立的膀胱癌中进行了多瘤病毒(PyV)大 T 抗原(LTAg)的免疫组化染色。总体而言,通过 RNA-seq 或 IHC-LTAg,我们在 1010 例膀胱癌中检测到了 26 例具有显著更高检出率的 PyV(P=4.4×10-5),其中非肌层浸润性膀胱癌(NMIBC)为 25/554(4.5%),肌层浸润性膀胱癌(MIBC)为 1/456(0.2%)。在 NMIBC 亚组中,FGFR3/PIK3CA APOBEC 型驱动突变在 PyV 阳性肿瘤中的检出率为 94.7%(18/19),而在 PyV 阴性肿瘤中的检出率为 68.3%(259/379)(P=0.011)。在 FGFR3 或 PIK3CA 突变的 NMIBC 亚组中,BKPyV 肿瘤阳性与 MIBC 进展的风险增加相关(P=0.019)。结论:我们的结果支持吸烟和 BKPyV 感染作为导致普通人群膀胱癌发生的危险因素,其通过不同的分子机制发挥作用。
吸烟可能导致膀胱癌中最常见的突变之一(FGFR3-Y375C),而病毒感染可能导致另外三个突变(FGFR3-S249C、PIK3CA-E542K 和 PIK3CA-E545K)。了解这些突变的原因可能会导致新的预防和治疗策略,例如病毒筛查和疫苗接种。